Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Supaglutide

A Study of Supaglutide in Chinese Type 2 Diabetes Patients

Shanghai Yinnuo Pharmaceutical Technology Co. · Phase 2 · Completed · Enrollment 40

NCT04314622

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Supaglutide (Part A)n/rn/rn/rn/r
Placebo(Part A)n/rn/rn/rn/r
Supaglutide (Part B)n/rn/rn/rn/r
Placebo (Part B)n/rn/rn/rn/r

Not shown

  • Supaglutide (Part A): endpoint not reported
  • Placebo(Part A): endpoint not reported
  • Supaglutide (Part B): endpoint not reported
  • Placebo (Part B): endpoint not reported